The US National Institutes of Health (NIH) and American biotechnology company Moderna have started human trials of a COVID-19 vaccine candidate, scientists announced…
The third-phase trial, dubbed COVE (Coronavirus Efficacy), will include around 30,000 US participants at multiple clinical sites. The trial will give participants 100-microgram doses of the mRNA vaccine, which is called mRNA-1273, on the first day. Participants will also receive another 100-microgram dose of the vaccine 29 days later.
